> ## Content Index
> Fetch the complete content index at: https://chinapharmadesk.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# RemeGen feeds a second BAFF/APRIL drug into Vor Bio—mostly for warrants, not cash
- URL: https://chinapharmadesk.com/remegen-vor-bio-rc298-license/
- Published: 2026-11-13T09:01:48.000Z
- Updated: 2026-11-15T02:54:11.000Z
- Description: RemeGen (09995.HK / 688331.SS) added preclinical BAFF/APRIL inhibitor RC298 to its Vor Bio (NASDAQ: VOR) license for $10m cash, $46m in warrants (9.99% cap) and up to $300m dev milestones.
- Author: Lin Yi
- Tags: Desk analysis, Deals & BD, Pipeline, Autoimmune & Immunology

RemeGen Co., Ltd. (`HKEX: 09995` / `SSE: 688331`) has amended its autoimmune licensing pact with Boston-based Vor Biopharma Inc. (`NASDAQ: VOR`) to hand over ex-Greater China rights to RC298, a preclinical long-acting dual BAFF/APRIL fusion protein, for roughly $56 million in upfront value—split between $10 million in cash and pre-funded warrants for 2.3 million Vor shares valued at about $46 million—plus up to $300 million in development and commercial milestones. Executed after U.S. market hours on November 11 and disclosed across [HKEX](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1112/2026111201370.pdf?ref=chinapharmadesk.com), [Shanghai Stock Exchange Notice No. 2026-057](https://static.cninfo.com.cn/finalpage/2026-11-13/1225669963.PDF?ref=chinapharmadesk.com), and [Vor’s SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1817229/000119312526456955/vor-20261111.htm?ref=chinapharmadesk.com), the deal remains an early-stage bet: RC298 is still in IND-enabling studies ahead of an expected China IND filing in the first half of 2027.

Headline biobucks suggest a $356 million expansion. The cash ratio tells the real story.

Only 18% of the $56 million upfront arrives in cash. That is half the 36% cash share RemeGen accepted in June 2025, when it rescued Vor—one month after the former cell-therapy biotech laid off 95% of its staff—by licensing ex-Greater China rights to marketed autoimmune drug telitacicept for $45 million in cash and $80 million in warrants (16 million post-split shares at a $0.002 exercise price). Instead of shopping its next-generation successor to a multinational balance sheet for hard cash, RemeGen is doubling down on its U.S.-listed partner shell.

## Two BAFF/APRIL deals, one equity-heavy template

| Term                             | June 2025 Original License (Telitacicept)                                      | Nov 2026 Amended License (RC298)                                             |
| -------------------------------- | ------------------------------------------------------------------------------ | ---------------------------------------------------------------------------- |
| **Asset & stage at signing**     | Telitacicept (weekly TACI-Fc); China-approved, global Phase 3                  | RC298 (engineered long-acting TACI-Fc); IND-enabling                         |
| **Territory granted to Vor**     | Worldwide excluding Greater China                                              | Worldwide excluding Greater China                                            |
| **Upfront cash**                 | $45 million (36% of upfront)                                                   | $10 million (18% of upfront)                                                 |
| **Upfront equity / warrants**    | Warrants for 16.0m shares ($0.002 strike; $80m stated value)                   | Pre-funded warrants for 2.3m shares ($0.0001 strike; \~$46m at Nov 11 close) |
| **Asset-specific milestones**    | Up to $330 million regulatory milestones (per SEC 8-K)                         | Up to $300 million ($20m on early clinical & tech-transfer goals)            |
| **Sales milestones & royalties** | Up to $3.775 billion sales milestones; high-single-digit to mid-teen royalties | Pooled into the same $3.775 billion sales-milestone and royalty tier         |

Why would Vor pay mostly in paper when it is sitting on nearly half a billion dollars? According to [Vor’s Q3 2026 Form 10-Q](https://www.sec.gov/Archives/edgar/data/1817229/000119312526439905/vor-20260930.htm?ref=chinapharmadesk.com), the company held $481.6 million in cash, cash equivalents, and marketable securities as of September 30, 2026—a war chest raised alongside the 2025 pivot to fund three expensive global registrational trials of telitacicept across generalized myasthenia gravis (gMG) and Sjögren’s disease into early 2029\. Preserving cash keeps that clinical runway intact.

For RemeGen, which reported roughly RMB 5.13 billion (approx. $713 million) in cash and short-term investments at mid-2026, an extra $10 million does little to move its domestic balance sheet. What the amendment solves is a franchise problem. Across global immunology, dual BAFF/APRIL blockade has shifted toward extended-interval dosing led by Vertex Pharmaceuticals’ monthly subcutaneous candidate povetacicept (acquired via the $4.9 billion Alpine Immune Sciences buyout) and Vera Therapeutics’ atacicept. Telitacicept’s weekly injection schedule leaves an opening for longer-acting rivals. Had RemeGen licensed RC298 to a third party outside China, it would have created a direct competitor to Vor’s sole commercial engine—and diluted the value of RemeGen’s existing 16-million-share warrant stake.

## What the U.S. SEC filing discloses that the Chinese notices omit

Reading RemeGen’s Hong Kong and Shanghai announcements alongside Vor’s SEC filings exposes four operational details absent from the Chinese-market summaries:

1. **Ownership blockers cap governance creep:** Although RemeGen’s cumulative warrant stack now covers 18.3 million Vor shares (following Vor’s 1-for-20 reverse stock split in September 2025), Vor’s Form 8-K specifies that exercising the new 2.3-million-share warrant is subject to a **9.99% beneficial ownership cap**, which can be raised to at most **19.99%** only upon 61 days’ prior notice. Combined with a Joint Steering Committee where Vor holds final decision-making authority outside Greater China, the structure gives RemeGen economic upside without triggering corporate control or CFIUS-sensitive governance thresholds.
2. **Fast-track resale registration with penalties:** Concurrent with the amendment, Vor signed a Registration Rights Agreement requiring it to file a Form S-3 resale shelf within 30 days of November 11 and secure SEC effectiveness within 75 days of initial filing, backed by capped liquidated damages if deadlines slip. Until a registration statement is effective, the warrant can only be exercised on a cashless basis.
3. **Pooled sales tiers accelerate downstream payouts:** Both filings note that sales milestones and royalties apply on an “aggregated basis across all licensed products,” while the SEC 8-K quantifies the shared commercial ceiling at **up to $3.775 billion** in sales milestones plus high-single-digit to mid-teen royalties. Pooling net sales means RC298, if approved years after telitacicept, would stack onto telitacicept’s established revenue base rather than restarting from the bottom royalty tier.
4. **China Phase 1 stays on RemeGen’s clock:** Vor’s [Exhibit 99.1 release](https://www.sec.gov/Archives/edgar/data/1817229/000119312526456955/vor-ex99%5F1.htm?ref=chinapharmadesk.com) places RC298’s anticipated China IND submission in **H1 2027**. Under the division of labor, RemeGen leads preclinical and China Phase 1 development—with both companies contributing—before handing ex-Greater China Phase 2/3 trials and regulatory filings to Vor.

## Next evidence triggers

Three concrete checkpoints will test whether this two-asset structure pays off: Vor’s Form S-3 resale filing due by mid-December 2026, RemeGen’s China IND submission for RC298 in H1 2027, and initial global Phase 3 gMG topline data for telitacicept expected in the first half of 2027—the catalyst that ultimately governs what Vor’s warrant paper is worth.

*Related on China Pharma Desk:* [*HighField’s TLL-018 tops tofacitinib on week-24 ACR50 in Phase 3 RA*](https://chinapharmadesk.com/highfield-tll018-ra-phase3/) *·* [*China Pharma Intelligence Guide: Cross-border licensing & 18A disclosures*](https://chinapharmadesk.com/start-here/)